Video: How many PD-1/L1 drugs do we need? Where is immunotherapy headed? Watch Jay Bradner, Hervé Hoppenot, Ellen Sigal, David Berman, Gideon Blumenthal, and Aiman Shalabi discuss with Endpoints at #JPM18
SAN FRANCISCO — In front of a packed house on Tuesday at the Endpoints News breakfast panel during #JPM18, Aiman Shalabi, CMO at the Cancer Research Institute kicked proceedings off with his research on the exploding PD-1/L1 pipeline, continuing on through the number of cancer immunotherapy products his group is tracking.
That’s a lot of possible redundancy and inefficiencies, Shalabi said. And just how can we harness all this effort in the most efficient manner?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.